67382-14-3

Basic information

• Product Name: 2-BROMO-1-(3-METHYL-1-BENZOFURAN-2-YL)ETHANONE
• Synonyms: 2-Bromo-1-(3-methyl-benzofuran-2-yl)-ethanone;2-bromo-1-(3-methyl-1-benzofuran-2-yl)ethan-1-one
• CAS NO: 67382-14-3
• Molecular Formula: C11H9BrO2
• Molecular Weight: 253.09
• Mol File: 67382-14-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 328.2°C at 760 mmHg
• Flash Point: 152.3°C
• Appearance: /
• Density: 1.512g/cm³
• Vapor Pressure: 0.000192mmHg at 25°C
• Refractive Index: 1.622
• CAS DataBase Reference: 2-BROMO-1-(3-METHYL-1-BENZOFURAN-2-YL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(3-METHYL-1-BENZOFURAN-2-YL)ETHANONE(67382-14-3)
• EPA Substance Registry System: 2-BROMO-1-(3-METHYL-1-BENZOFURAN-2-YL)ETHANONE(67382-14-3)

Safety Data

• Hazardous Substances Data: 67382-14-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H9BrO2/c1-7-8-4-2-3-5-10(8)14-11(7)9(13)6-12/h2-5H,6H2,1H3

Upstream product

• 23911-56-0 2-acetyl-3-methylbenzofuran 
• 118-93-4 o-hydroxyacetophenone 
• 1878-62-2 2-(2-acetylphenoxy)acetic acid 
• 63815-27-0 2-(2'-acetylphenoxy)acetic acid ethyl ester 
• 21535-97-7 3-methyl-benzofuran 
• 22118-09-8 2-bromoacetyl chloride 

Relevant articles and documents

TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE

The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.